Studies of Femara at lower dosages?
Meet the Experts
Ruth Oratz, M.D., F.A.C.P. is associate professor of clinical medicine at New York University School of Medicine. She is the founder of The Women's Oncology & Wellness Practice in New York City where she specializes in treating women with breast cancer and other malignancies, as well as those at risk for cancer.
Beth Baughman DuPree, M.D., F.A.C.S. is a general surgeon with a focus in breast cancer care and the CEO and medical director of the Comprehensive Breast Care Institute at DSI of Bucks County, PA.
Question from Susie: Are there any ongoing studies for Femara at lower doses?
- Answer —Ruth Oratz, M.D., F.A.C.P.: No. We've done many clinical trials with all of the aromatase inhibitors, and the current doses that are approved and in clinical use have been carefully delineated in large clinical trials.
On Wednesday, September 20, 2006, our Ask-the-Expert Online Conference was called Open for Your Questions. Ruth Oratz, M.D., F.A.C.P. and moderator Beth Baughman DuPree, M.D., F.A.C.S. answered your questions covering a wide variety of issues relating to breast cancer.
The materials presented in these conferences do not necessarily reflect the views of breastcancer.org. A qualified healthcare professional should be consulted before using any therapeutic product or regimen discussed. All readers should verify all information and data before employing any therapies described here.
A production of LiveWorld, Inc.
Copyright 2008. All rights reserved.